Preprint Review Version 1 This version is not peer-reviewed

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

Benjamin Derman
* ORCID logo ,
Carlyn Tan
,
Ian Steinfield
,
Florence R. Wilson
,
Dee Lin
,
Bingcao Wu
,
Mariana Fernandez
,
Jessica Fowler
,
Agne Paner-Straseviciute
,
Nina Kim
,
Margaret Doyle
,
Alexander Marsh
,
Jessica Cheadle
,
Sam Keeping
,
Jane Jijun Liu
Version 1 : Received: 9 October 2024 / Approved: 10 October 2024 / Online: 10 October 2024 (09:47:05 CEST)

How to cite: Derman, B.; Tan, C.; Steinfield, I.; Wilson, F. R.; Lin, D.; Wu, B.; Fernandez, M.; Fowler, J.; Paner-Straseviciute, A.; Kim, N.; Doyle, M.; Marsh, A.; Cheadle, J.; Keeping, S.; Liu, J. J. Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review. Preprints 2024, 2024100776. https://doi.org/10.20944/preprints202410.0776.v1 Derman, B.; Tan, C.; Steinfield, I.; Wilson, F. R.; Lin, D.; Wu, B.; Fernandez, M.; Fowler, J.; Paner-Straseviciute, A.; Kim, N.; Doyle, M.; Marsh, A.; Cheadle, J.; Keeping, S.; Liu, J. J. Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review. Preprints 2024, 2024100776. https://doi.org/10.20944/preprints202410.0776.v1

Abstract

Teclistamab (TEC) is the first B-cell maturation antigen-directed bispecific antibody approved by the European Medicines Agency and Food and Drug Administration for triple-class exposed relapsed/refractory multiple myeloma (RRMM). As TEC is increasingly being used in real-world (RW) settings, this study sought to gather existing RW evidence on effectiveness, safety, healthcare resource utilization, and clinical practices associated with TEC. A systematic literature review was performed to identify RW observational studies of adults with RRMM treated with TEC. Sixty-one records representing 41 unique studies were included; sample sizes ranged from 8 to 572 patients. Where reported, median follow-up ranged from 2.3 to 33.6 months and more than 65% of patients would have been ineligible for the pivotal trial of TEC (MajesTEC-1) in all but one study. Across populations with ≥50 patients, overall response rates ranged from 50 to 66% and cytokine release syndrome (CRS) rates ranged from 18 to 64%. Tocilizumab use for CRS management was reported in 14 studies, with two indicating lower CRS rates (13% and 26%) when used prophylactically. Survival and infection outcomes showed wide variability due to short follow-up in most studies. Overall, early RW effectiveness and safety outcomes of TEC were comparable to findings from MajesTEC-1.

Keywords

systematic literature review; real-world data; relapsed-refractory multiple myeloma; bispecific antibodies; B-cell maturation antigen; teclistamab; cytokine release syndrome; immune effector cell-associated neurotoxicity syndrome

Subject

Medicine and Pharmacology, Hematology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.